Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cryo-Cell International to Present at the Q3 Virtual Investor Summit

CCEL

Oldsmar, Florida--(Newsfile Corp. - August 11, 2021) - Cryo-Cell International (OTC Pink: CCEL) today announced that David Portnoy, Chairman of the board and Co-CEO, will be attending the Q3 Virtual Investor Summit.

Event Q3 Investor Summit
Date August 17-18th, 2021
Presentation August 18th at 02:45 PM ET
Location https://zoom.us/webinar/register/WN_mUXIsyaBSl6hpoY8M7ZNpA

About Cryo-Cell International

Founded in 1989, Cryo-Cell International Inc., the world’s first private cord blood bank, is internationally recognized as the industry leader. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. Cryo-Cell aims to help more patients significantly improve their lives through the utilization of the unique immunomodulatory and potential regenerative properties found in the cord blood and cord tissue. In February 2021, Cryo-Cell entered into an exclusive, collaborative license agreement with Duke University that grants Cryo-Cell the rights to intellectual property, proprietary processes and regulatory/clinical data related to cord blood and cord tissue developed at The Marcus Center for Cellular Cures at Duke University. Cryo-Cell is scheduled to open its first infusion clinic by 2022, to treat patients with conditions such as autism, cerebral palsy, and traumatic brain injuries under the rights granted to Duke University through the FDA’s Expanded Access Program. In addition to these, the license agreement includes other clinical indications currently being studied, such as adult stroke, multiple sclerosis, osteoarthritis and COVID-19.Cryo-Cell’s mission is to provide clients with premier cord blood and cord ‎tissue cryopreservation services, raise awareness of the opportunity for expectant parents ‎to bank or donate their baby’s cord blood and support the advancement of regenerative ‎medicine.

For further information:

Cryo-Cell International
Diane Glanz, PharmD, RPh
8137492195
dglanz@cryo-cell.com

About the Investor Summit

The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q3 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.

To request complimentary investor registration: please click here: Complimentary Investor Registration

Contact:

Sasha Murray at sasha@investorsummitgroup.com